Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Patients With Diabetic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
Circulation 2023 Aug 22;148(8)651-660, JL Januzzi, R Mohebi, Y Liu, N Sattar, HJL Heerspink, E Tefera, M Vaduganathan, J Butler, Y Yavin, J Li, CA Pollock, V Perkovic, B Neal, MK HansenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.